Our findings suggest that inhibiting fibroblast β2AR might be an important mechanism through which β-blockers are decreasing cardiac fibrosis and targeting β2AR may be an effective therapeutic strategy for the treatment of heart failure. This evidence concerns the gene ADRB2 and heart failure.